Octet® RH96 BLI System

In this application note, Sartorius demonstrates the power of using the Ambr® 15 Cell Culture system with an integrated Vi-CELL XR and Ambr® Analysis Module together with an Octet® to identify optimum yield conditions in media screening and process optimization experiments.

This application note describes the method setup process for a successful protein-small molecule binding interactions analysis on Octet® R2, R4, R8, RH16, and RH96 instruments. Discover tips on best practices for the preparation of optimal reagents for small molecule binding studies and data analysis including data referencing procedures.

The determination of drug analyte characteristics can be affected by the test method used. In this application note, Sartorius discusses the strategies for the development and validation of a potency assay using Octet® systems. We have highlighted the Octet® system’s ease-of-use and fast time to results by showcasing strategies for the development and validation of a method for evaluating the binding of an Fc gamma receptor III molecules to the widely characterized NISTmAb.

Affinity constants are a key property for determining the degree of interactions between candidate therapeutic molecules and their target receptors. Download this application note to find out how the Octet® System can help advance your biotheraputic research.

This application note describes the Octet® platform, biosensors, and assay kits that offer intermediate and high throughput capabilities for titer, host cell protein analysis, residual protein A detection, and sialic acid content detection and the associated time and cost savings.

This application note presents a vaccine potency assay performed using Octet systems, in which samples are analyzed in their natural state without the use of detergents. Octet systems are capable of analyzing whole virus, split virions and recombinant HA vaccine samples.

Accounting for at least 15% of all human pathogens, emerging infectious diseases (EID) pose a significant burden on public health. Vaccination represents one of the most successful prophylactic tools for disease prevention and control, however, the development process is typically lengthy and expensive. While there has been a rapid development of multiple safe and highly effective vaccines in response to the current COVID-19 pandemic, there are still many challenges to overcome. This application note will explore the common challenges of vaccine development and the solutions available to overcome them.

In this application note, Sartorius details how the Octet® systems can be used for rapid titer of antibody clones to enable quick selection of high-producing clones.

Your research should be guided by your imagination, not by the limitations of your label-free system. In this brochure, Sartorius introduces the Octet® platform's, with flexible, open-format design and comprehensive menu of biosensors letting you attack research challenges in unique new ways.

Recent advancements in the field of biologics, whether in terms of research, development or production, have been greatly attributed to real-time label-free (RT-LF) technologies. This biosensor-based technology is especially crucial for the characterization of molecular interactions across various stages in biopharmaceutical discovery, development and production.

Download this eBook to explore the best practices and protocols to generate high-quality data quickly and easily using the Octet® BLI platform – designed to offer a comprehensive solution for your protein characterization needs. From vaccine potency to quantitative screening of bispecific antibodies, you'll find a range of applications designed to help you:

• Avoid later-stage failures
• Rapidly screen large antibody libraries
• Evaluate diverse assay conditions
• Fast-track development

Wednesday, September 17, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT

Join Anja Wille as she explores how Sanofi has transformed antibody therapeutic development through advanced automation and screening technologies. Discover an end-to-end automated platform to engineer next-generation multi-specific antibody therapeutics at unprecedented scale.

She will cover the shift from traditional workflows to high-throughput platforms handling 10,000+ variants, and how the integration of multiple robotic platforms streamlines DNA handling, protein expression, and analysis.

The webinar will highlight how this integrated approach has successfully executed over 30 campaigns, significantly increasing the probability of success while generating valuable data for machine learning and AI applications.

Plus, you will learn about the use of biolayer interferometry (BLI) technology for rapid quantitation and off-rate screening and see real-world success stories, including Fab affinity maturation campaigns.

Key learning objectives:

• Understand how an integrated automated platform transforms traditional antibody development into a high-throughput process capable of handling 10,000+ variants simultaneously
• Learn about the implementation and benefits of BLI technology for rapid quantitation and off-rate screening, including practical insights from real campaign data
• Discover how automation across the entire value chain (from DNA handling to protein analysis) increases the probability of success and generates valuable data for AI applications

Who should attend?

• Biopharmaceutical R&D scientists - Particularly those working in antibody engineering, protein science, and therapeutic development
• Laboratory automation specialists - Professionals interested in high-throughput screening technologies and workflow optimization
• Assay development scientists - Those working with or interested in BLI technology applications for quantitation and binding kinetics
• Bioprocess engineers - Professionals involved in scaling antibody production and quality assessment
• Research directors and managers - Decision-makers evaluating technologies to enhance R&D productivity and efficiency
• Academic researchers - Scientists in immunology, protein engineering, and biotherapeutics development seeking insights into industrial-scale approaches

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

Commercialization of a biologic is a lengthy and expensive process. Successful cell line development (CLD) is heavily dependent upon balancing time and resources with acquiring high-quality data for informed decisions. Each stage of the CLD workflow has challenges and there is a real need for advanced strategies and intelligent use of innovative solutions.

The CellCelector, iQue®, Octet®, and Ambr® 15 CC platforms are perfectly designed to seamlessly work together to streamline the early CLD workflow, enabling data-driven decisions and reducing risk during later stages of biologic development. In this webinar, Dr. Fern Slingsby, Ambr Product Specialist at Sartorius and Dr. Daryl Cole, Applications Scientist at Sartorius, will explain how integration of these platforms can be achieved, and where they best fit into the cell line development workflow.

Key learning objectives

• Learn about the early CLD workflow and the bottlenecks associated with the various stages
• Discover instruments which are suited to high-throughput demands and where they fit into the CLD workflow
• Establish a strategy for a simplified approach to cell line development

Who should attend?

• Analytical scientists and researchers involved in early drug discovery and cell line development
• Bioprocessing engineers and scientists
• Process development engineers and scientists
• Lab managers

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Assessing AAV vector quality in gene therapy manufacturing is crucial, but the current gold standard, serotype-specific ELISA, has its drawbacks — time-consuming and prone to matrix effects. In this webinar, Dr. Yoann Saucereau from ExcellGene reveals how a label-free approach not only cut down on complexities in biological matrices but also enabled a quick, routine method. Now, ExcellGene effortlessly analyzes up to 96 samples in under 30 minutes for efficient AAV platform development.

Key learning objectives

• Explore how suitable QC workflows are established in AAV development and manufacturing
• Discover the critical role of assay design and development to determine correct binding kinetics, affinity values or analyte concentrations
• Consider the optimization and evaluation of an AAV titer assay in comparison to Octet® AAVX Biosensors

Who should attend?

• Lab researchers

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Dustin Whitson, an applications consulting scientist at Biosero, shares how the company is working to achieve its mission to enhance scientific discovery through software and laboratory automation.

Whitson introduces Biosero's recent partnership with Sartorius, integrating the Octet® BLI platform with Biosero's automation and software capabilities, with the goal of putting the power of automation in the hands of more scientists to help accelerate drug discovery.

This video was filmed at SLAS2025.

Dr. Nilshad Salim, Global Product Manager at Sartorius, introduces an exciting new integration of the Octet® BLI platform with Biosero’s automation capabilities and Green Button Go software.

Learn how this integration will enhance the measurement of binding strength, kinetics, and protein concentration, with the increased automation enabling labs to efficiently analyze thousands of samples, significantly improving operational efficiency.

This video was filmed at SLAS2025.

Watch this video to find out about the high-throughput applications of Sartorius' Octet Systems.

Learn why so many choose ForteBio Octet® Systems in these customer testimonials.

Download our new eBook presenting optimal label-free approaches to generate high-quality data fast

Take a look at what other researchers and scientists are saying about cutting-edge technologies in engineered antibodies

From immunoassays and ELISAs to multi-mode microplate readers, discover the technologies making a difference for other scientists in your field

Discover how using Protein A and His1K biosensors can reduce the time of screening for bispecific antibodies

In this SelectScience special feature dedicated to protein biology, discover methods to improve your experiments